Amantadine augmentation for refractory obsessive-compulsive disorder: A case report

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 85-86

  Pasquini, Massimo ^a   Berardelli, Isabella ^a   Biondi, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE; VENLAFAXINE;

ADULT; CASE REPORT; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; LETTER; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; WECHSLER INTELLIGENCE SCALE;

ADULT; AMANTADINE; CLOMIPRAMINE; DRUG THERAPY, COMBINATION; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 74549196310     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c8b44f     Document Type: Letter

References (19)

1. Starck G, Ljungberg M, Nilsson M, et al. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm. 2008;115:1051-1062.
2. Rosenberg DR, Keshavan MS. A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry. 1998;43:623-640.
3. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30:1735-1740.
4. Rotge JY, Guehl D, Dilharreguy B, et al. Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biol Psychiatry. 2009;65:75-83.
5. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3:69-81. (Pubitemid 43276634)
6. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychol. 2005;58:424-428.
7. Grant P, Lougee L, Hirschtritt M, et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Child Adolesc Psychopharmacol. 2007;17:761-767.
8. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology. 2006;184:254-256. (Pubitemid 43084809)
9. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmentated exposure therapy for obsessive-compulsive disorder. Biol Psych. 2007;62:835-838.
10. Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psych. 2005;162:2191-2192.
11. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1173-1175.
12. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009;29:51-55.
13. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42:81-93.
14. Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2008;43:664-670.
15. Salkovskis PM. Understanding and treating obsessive-compulsive disorder. Behav Res Ther. 1999;37:29-52.
16. Owen JCE, Whitton PS. Effects of amantadine and budipine on antidepressant drugYevoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br J Pharmacol. 2005;145:587-592.
17. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005;25: 3312-3322.
18. Onogi H, Ishigaki S, Nakagawasai O, et al. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral. Biol Pharm Bull. 2009;32: 850-855.
19. Chang KC, Kim MK, Wee WR, et al. Corneal endothelial dysfunction associated to amantadine toxicity. Cornea. 2008;27: 1182-1185.